Peter Schneider (University of California, San Francisco, USA) is joined by Sabine Steiner (Vienna, Austria), Mårten Falkenberg (Sahlgrenska University Hospital and the University of Gothenburg, Gothenberg, Sweden) and Koen Deloose (AZ Sint-Blasius Hospital, Dendermonde, Belgium) for a Charing Cross (CX) Symposium roundtable discussion on the use of drug-based technology use in the lower extremity in light of the SWEDEPAD 2 trial results and the subsequent European Society for Vascular Surgery (ESVS) updated recommendations on the management of asymptomatic peripheral arterial disease (PAD) and intermittent claudication.
